Drug Trial Radar · NCT06131437
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
809
Actual
Start
Nov 27, 2023
Primary completion
Dec 8, 2025
Study completion Jan 9, 2026
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Nov 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medicine will be gradually increased until reaching the planned dose (2.4 mg CagriSema or 15 mg Tirzepatide). The study will last for about one and a half year for each participant.
Conditions
- Obesity
Interventions
CagrilintideDrug
Cagrilintide will be administered subcutaneously.
SemaglutideDrug
Semaglutide will be administered subcutaneously.
TirzepatideDrug
Tirzepatide will be administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To confirm non-inferiority of CagriSema versus tirzepatide: Relative change in body weightTime frame: From baseline (week 0) to end of treatment (week 84)
Locations
46 sites in 1 country. Site status is shown where the registry gives one.
Univ of Alabama Birmingham
Birmingham, Alabama
Chambliss Clinical Trials LLC
Montgomery, Alabama
FDRC
Costa Mesa, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Univ of Colorado at Denver
Aurora, Colorado
Yale University School Of Medicine
New Haven, Connecticut
Northeast Research Institute
Fleming Island, Florida
Jacksonville Ctr For Clin Res
Jacksonville, Florida
South Broward Research LLC
Miramar, Florida
Hope Clin Res & Wellness
Conyers, Georgia
East West Med Res Inst
Honolulu, Hawaii
Great Lakes Clinical Trials
Chicago, Illinois
Endeavor Health
Skokie, Illinois
Evanston Premier Hlthcr Res
Skokie, Illinois
Midwest Inst For Clin Res
Indianapolis, Indiana
Northern Pines Hlth Ctr, PC
Buckley, Michigan
StudyMetrix Research LLC
City of Saint Peters, Missouri
Comprehensive Weight Ctrl Prog
New York, New York
University of North Carolina
Chapel Hill, North Carolina
Medication Mgmnt, LLC_Grnsboro
Greensboro, North Carolina
PharmQuest Life Sciences LLC
Greensboro, North Carolina
Accellacare_NC
Raleigh, North Carolina
Accellacare
Wilmington, North Carolina
New Venture Medical Research
Wadsworth, Ohio
Lynn Institute of Norman
Norman, Oklahoma
The University of Penn Center
Philadelphia, Pennsylvania
Clinical Res Collaborative
Cumberland, Rhode Island
Medical University Of South Carolina
Charleston, South Carolina
Coastal Carolina Res Ctr
North Charleston, South Carolina
Hillcrest Clinical Research
Simpsonville, South Carolina
Spartanburg Medical Research
Spartanburg, South Carolina
Holston Medical Group_Bristol
Bristol, Tennessee
Holston Medical Group
Kingsport, Tennessee
Amarillo Med Spec LLP
Amarillo, Texas
Elligo Clin Res Centre
Austin, Texas
UT Health University of Texas
Bellaire, Texas
Baylr Sctt White Rs Inst, Endo
Dallas, Texas
Velocity Clin Res, Dallas
Dallas, Texas
UT Southwestern Medical Center-CRU
Dallas, Texas
DCOL Ctr for Clin Res
Longview, Texas
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.